Fucoidan Clinical Evidence: A PharmD's Research Review

Dai Tran, PharmD, MBA, B.S.

CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed Pharmacist

Clinical Insights Series • APhA Immunization Certified • 10+ Years Clinical Experience

Why I Built This Reference Library

In my decade of clinical practice, fucoidan is one of the supplements I get asked about most — and also one of the most misrepresented. Patients come in with printouts from wellness blogs, MLM company pages, or Amazon listings making dramatic claims with no citations. My job as a pharmacist is to cut through that noise.

This is my personally curated, evidence-labeled reference library. Every citation has been individually verified. I distinguish between human clinical trials, preclinical/laboratory research, and scientific reviews so you can evaluate the strength of the evidence yourself. For human studies, I also disclose materially relevant funding, material-provider, compensation, or author-affiliation information when it is reported in the indexed record.

If you want to discuss whether fucoidan is appropriate for your specific health situation, call us at (408) 622-8068 or send us a message. A free pharmacist consultation is always available.

What Is Fucoidan?

Fucoidan is a sulfated polysaccharide found primarily in the cell walls of brown seaweed species including Okinawa Mozuku (Cladosiphon okamuranus), Mekabu (Undaria pinnatifida), and Bladderwrack (Fucus vesiculosus). It has been studied extensively in Japan, Australia, and South Korea for its immune-modulating, anti-inflammatory, antioxidant, and potential anti-tumor properties.

The products we carry at Khang Pharmacy — NatureMedic® and Umi No Shizuku — use Okinawa Mozuku-sourced fucoidan, which has been investigated in human and preclinical research. However, evidence for a source or preparation should not be treated as proof that a finished commercial product has been proven to produce the same outcomes.

Immune Function & Immune Modulation

1. HUMAN RCT
   Tomori M, et al. Effects of Ingesting Fucoidan Derived from Cladosiphon okamuranus Tokida on Human NK Cells: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Pilot Study. Marine Drugs. 2021;19(7):340. PMID: 34203925
   40 healthy adults; 3 g/day for 12 weeks. A between-group NK-cell effect was observed specifically in male participants at 8 weeks. A blanket increase in NK activity across all participants was not demonstrated and should not be inferred from this study. Provenance: PubMed reports that investigators received compensation and that South Product supplied the test material. This is material context, not proof that the result is invalid.
2. HUMAN STUDY
   Nagamine T, et al. Activation of NK cells in male cancer survivors by fucoidan extracted from Cladosiphon okamuranus. Molecular and Clinical Oncology. 2020;12(2):81–88. PMID: 31814980
   Open-label study in 11 cancer survivors; 3 g/day for six months. NK activity did not significantly increase in the overall study group. The significant increase was observed in male participants only. This study should not be summarized as a blanket NK-cell activation finding. Provenance: PubMed lists three authors as affiliated with South Product Co., Ltd. This relationship is relevant context when interpreting the findings but does not by itself invalidate the study.
3. PRECLINICAL
   Maruyama H, et al. The role of NK cells in antitumor activity of dietary fucoidan from Undaria pinnatifida sporophylls (Mekabu). Planta Medica. 2006. PMID: 17054048
4. PRECLINICAL
   Synytsya A, et al. Mekabu fucoidan: structural complexity and defensive effects against avian influenza A viruses. Carbohydrate Polymers. 2014;111:633–644. PMID: 25037398
5. REVIEW
   Fitton JH, Stringer DN, Karpiniec SS. Therapies from Fucoidan: An Update. Marine Drugs. 2015;13(9):5920–5946. PMID: 26389927

Cellular & Antioxidant Research

6. REVIEW
   Li B, Lu F, Wei X, Zhao R. Fucoidan: Structure and Bioactivity. Molecules. 2008;13(8):1671–1695. PMID: 18794778
7. REVIEW
   Ngo DH, Kim SK. Sulfated polysaccharides as bioactive agents from marine algae. International Journal of Biological Macromolecules. 2013;62:70–75. PMID: 23994790
8. REVIEW
   Wang Y, et al. Biological Activities of Fucoidan and the Factors Mediating Its Therapeutic Effects: A Review of Recent Studies. Marine Drugs. 2019;17(3):183. PMID: 30897733
9. PRECLINICAL
   Senni K, et al. Fucoidan a sulfated polysaccharide from brown algae is a potent modulator of connective tissue proteolysis. Archives of Biochemistry and Biophysics. 2006. PMID: 16364234

Healthy Inflammatory Response

10. HUMAN STUDY
    Takahashi H, et al. An Exploratory Study on the Anti-inflammatory Effects of Fucoidan in Relation to Quality of Life in Advanced Cancer Patients. Integrative Cancer Therapies. 2018;17(2):282–291. PMID: 28627320
    Prospective open-label single-arm study in 20 patients with advanced metastatic cancer receiving fucoidan for at least four weeks. IL-1β, IL-6, and TNF-α decreased after two weeks, while quality-of-life measures including fatigue remained largely stable without significant improvement. Because there was no control group, these biomarker changes cannot establish that fucoidan caused the effect or improved clinical outcomes. The findings are preliminary and hypothesis-generating.
11. PRECLINICAL
    Cumashi A, et al. A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds. Glycobiology. 2007;17(5):541–552. PMID: 17296677
12. REVIEW
    Fitton JH. Therapies from fucoidan; multifunctional marine polymers. Marine Drugs. 2011;9(10):1731–1760. PMID: 22072995

Digestive & Gut Microbiome Health

13. HUMAN RCT
    Wang S, et al. Effect of fucoidan on gut microbiota and its clinical efficacy in Helicobacter pylori eradication: A randomized controlled trial. Frontiers in Cellular and Infection Microbiology. 2023. PMID: 37548312
    Open-label randomized trial in 90 H. pylori-positive patients comparing standard quadruple therapy with fucoidan-assisted treatment strategies. Fucoidan-containing strategies were associated with differences in gut-microbiome composition and gastrointestinal symptoms. These findings support investigation of fucoidan as an adjunct during eradication therapy but should not be interpreted as evidence that fucoidan independently eradicates H. pylori. Provenance: PubMed lists two authors as affiliated with Qingdao Bright Moon Seaweed Group Co., Ltd.
14. HUMAN RCT
    Effects of fucoidan and synbiotics supplementation during bismuth quadruple therapy of Helicobacter pylori infection on gut microbial homeostasis. 2024. PMID: 39010853
    Open-label randomized trial; 80 H. pylori-infected patients across four groups (quadruple therapy, fucoidan, synbiotics, combination). H. pylori eradication rates did not differ significantly between groups. Meaningful differences were observed in gut microbiome composition. Appropriate framing: microbiome-support research — not evidence that fucoidan improves H. pylori eradication rates.
15. PRECLINICAL
    Shibata H, et al. Inhibitory effect of Cladosiphon fucoidan on the adhesion of Helicobacter pylori to human gastric cells. Journal of Nutritional Science and Vitaminology. 1999. PMID: 10524351

Supportive Oncology Research

16. HUMAN RCT
    Tsai HL, et al. Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial. Marine Drugs. 2017. PMID: 28430159
    In 54 enrolled participants, the trial’s defined primary endpoint, disease-control rate, was 92.8% with fucoidan versus 69.2% with control (p=0.026). This is a positive result for that prespecified endpoint in a specific low-molecular-weight fucoidan preparation and metastatic colorectal-cancer treatment context. The sample was small, and the result does not by itself establish tumor control, survival benefit, or cancer-treatment efficacy for fucoidan generally or for other preparations.
17. HUMAN RCT
    Tsai HL, et al. The Auxiliary Effects of Low-Molecular-Weight Fucoidan in Locally Advanced Rectal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy Before Surgery. 2023. PMID: 37822243
    87-patient double-blind randomized trial. Some physical-well-being measures improved, but overall FACT-C improvements were not statistically significant under the study’s prespecified threshold. Some adverse effects and microbiome measures also differed between groups. The appropriate conclusion is that this specific preparation showed mixed, limited adjunctive findings in a defined rectal-cancer treatment setting — not proof of a general quality-of-life, microbiome, or cancer-treatment benefit.
18. HUMAN RCT
    Ikeguchi M, et al. Fucoidan reduces the toxicities of chemotherapy for patients with unresectable advanced or recurrent colorectal cancer. Oncology Letters. 2011. PMID: 22866084
    Small randomized study of 20 patients with unresectable advanced or recurrent colorectal cancer receiving FOLFOX or FOLFIRI, allocated to fucoidan (n=10) or control (n=10). Fucoidan was associated with less fatigue and longer continuation of chemotherapy. Survival was numerically longer but was not statistically significantly different between groups (P=0.314). The very small sample limits certainty, and the findings do not establish a survival benefit or general prevention of chemotherapy toxicity.
19. PRECLINICAL
    Aisa Y, et al. Fucoidan induces apoptosis of human HS-sultan cells accompanied by activation of caspase-3 and down-regulation of ERK pathways. American Journal of Hematology. 2005. PMID: 15609279
20. PRECLINICAL
    Yamasaki-Miyamoto Y, et al. Fucoidan induces apoptosis through activation of caspase-8 on human breast cancer MCF-7 cells. Journal of Agricultural and Food Chemistry. 2009. PMID: 19754176
21. PRECLINICAL
    Boo HJ, et al. The anticancer effect of fucoidan in PC-3 prostate cancer cells. Marine Drugs. 2013. PMID: 23966032
22. PRECLINICAL
    Maruyama H, et al. Antitumor activity and immune response of Mekabu fucoidan extracted from Sporophyll of Undaria pinnatifida. PMID: 12929574
23. REVIEW
    Atashrazm F, et al. Fucoidan and cancer: a multifunctional molecule with anti-tumor potential. Marine Drugs. 2015. PMID: 25874926
24. SYSTEMATIC REVIEW
    Effectiveness of Fucoidan on Supplemental Therapy in Cancer Patients: A Systematic Review. 2022. PMID: 35628061

Absorption, Bioavailability & Safety

25. HUMAN STUDY
    Absorption Study of Mozuku Fucoidan in Japanese Volunteers. Marine Drugs. 2018. PMID: 30061499
    396 volunteers; fucoidan detected in urine in 385/396 participants after ingestion. Detection in urine confirms that some oral absorption occurred. It does not establish high systemic bioavailability or clinical efficacy. Provenance: PubMed lists three of the four authors as affiliated with South Product Co., Ltd. This affiliation is relevant context for interpreting the absorption findings.
26. HUMAN STUDY
    Tokita Y, et al. Development of a fucoidan-specific antibody and measurement of fucoidan in serum and urine by sandwich ELISA. Bioscience, Biotechnology, and Biochemistry. 2010. PMID: 20139614
    Human methodological research describing fucoidan detection in serum and urine using a fucoidan-specific antibody and sandwich ELISA. This addresses measurement and distribution, not clinical benefit; it should not be interpreted as proof of high bioavailability or therapeutic efficacy.
27. HUMAN STUDY
    Irhimeh MR, et al. Pilot clinical study to evaluate the anticoagulant activity of fucoidan. Blood Coagulation & Fibrinolysis. 2009. PMID: 19696660
    10 participants received 3 g of 75% fucoidan; 10 received placebo. Although some coagulation parameters changed, the authors concluded that this oral fucoidan preparation did not appear to have meaningful oral anticoagulant activity, despite strong in-vitro anticoagulant properties. This study should not be cited as evidence that oral fucoidan is clinically anticoagulant.
28. HUMAN RCT
    Myers SP, et al. Effects of fucoidan from Fucus vesiculosus in reducing symptoms of osteoarthritis: a randomized placebo-controlled trial. Biologics. 2016. PMID: 27307702
    Double-blind randomized placebo-controlled trial in 122 adults with mild-to-moderate hip or knee osteoarthritis evaluating 300 mg/day of a Fucus vesiculosus extract containing 85% fucoidan for 12 weeks; 96 participants completed the study. Reduction in osteoarthritis symptoms was not significantly different from placebo. The preparation was generally well tolerated, with no clinically significant changes in measured blood safety parameters. This trial does not support a clinically meaningful osteoarthritis symptom benefit at the studied dose and formulation. Provenance: PubMed lists one author as affiliated with Marinova Pty Ltd.

Comprehensive Scientific Reviews

29. REVIEW [Cross-listed from entry 6]
    Li B, Lu F, Wei X, Zhao R. Fucoidan: Structure and Bioactivity. Molecules. 2008;13(8):1671–1695. PMID: 18794778
30. REVIEW [Cross-listed from entry 5]
    Fitton JH, Stringer DN, Karpiniec SS. Therapies from Fucoidan: An Update. Marine Drugs. 2015;13(9):5920–5946. PMID: 26389927
31. REVIEW
    Fitton JH, et al. Therapies from Fucoidan: New Developments. Marine Drugs. 2019. PMID: 31601041
32. REVIEW [Cross-listed from entry 8]
    Wang Y, et al. Biological Activities of Fucoidan and the Factors Mediating Its Therapeutic Effects: A Review of Recent Studies. Marine Drugs. 2019;17(3):183. PMID: 30897733

Evidence Maintenance & Freshness

PubMed publication dates move forward, but a responsible evidence library should not grow simply by accumulating citations. New publications are screened for relevance first, then classified as human, human plus preclinical, preclinical, protocol, commentary, review, or systematic review. A materiality assessment follows: a paper is added only when it meaningfully changes, qualifies, or strengthens the evidence map.

New general reviews and new animal or mechanistic papers may therefore be identified during reconciliation without being added automatically. Corrigenda and updated records are checked as part of that process. The 32-entry count above remains limited to publications that have been screened into this library rather than every new paper that mentions fucoidan.

Products Carrying Clinically Studied Fucoidan

At Khang Pharmacy, we carry two brands using Okinawa Mozuku-sourced fucoidan. That source has been investigated in human and preclinical research, but source-level or preparation-level evidence does not prove that any specific finished product prevents or treats disease:

• NatureMedic® line — View all NatureMedic® Fucoidan products →
• Umi No Shizuku line — View all Umi No Shizuku products →

Not sure which fucoidan product is right for you? Call (408) 622-8068 for a free pharmacist consultation.

Reviewed by: Dai Tran, PharmD, MBA, B.S.  View full bio →

CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed Pharmacist

Clinical Insights Series • APhA Immunization Certified • 10+ Years Clinical Experience

Khang Pharmacy | 2451 S King Rd., Ste A1, San Jose, CA 95122 | (408) 622-8068 | www.khangpharmacy.com